Key Highlights
● Revenue, Earnings and adjusted EBITDA rose
● Guidance was withdrawn
● No Earnings Call was held
● Sale to Clayton, Dubilier & Rice and McKesson awaits completion
Option Care Health, Inc. (NASDAQ:OPCH), a major name in US healthcare services, reported third-quarter results that showed net revenue, net income, Diluted Earnings per Share and adjusted EBITDA all rising from the prior-year quarter. What set the report apart was what it omitted. The Bannockburn, Illinois, company withdrew its previously disclosed financial guidance and said it would not hold an earnings call, because it has agreed to be acquired by Clayton, Dubilier & Rice, LLC and McKesson Corporation (NYSE:MCK).
The release is notably spare, and it reads differently from a typical results announcement, since the usual sections on outlook and strategy have effectively fallen away while the pending transaction runs its course. It presents tables and highlights, but no management quotes or narrative discussion of the period. The Merger agreement itself is not new. It was dated early in October and announced. The latest in-window development is the results release, which gives the market the first look at the company's operating performance since the deal was signed.
Option Care Health describes itself as "the nation's largest independent provider of home and alternate site infusion services." It employs thousands of team members, including a large clinical staff, and operates across every US state. Market data, in its report on the deal, described services including home and ambulatory infusions, specialty pharmacy and care for complex conditions.
Top-Line Growth With Margins Holding Roughly Level
Net Revenue climbed modestly from the prior-year quarter, a gain the Quarterly Report filed with the SEC breaks out by payer. Commercial payers accounted for the largest share of the increase, government payers contributed a smaller amount and patient revenue added a further piece. The report's financial statements do not by themselves explain the underlying therapy mix, and with no call taking place, management did not offer a verbal account of what drove the performance.
Gross profit grew at a pace close to revenue, leaving gross Margin only slightly higher than a year earlier. Selling, general and administrative expense rose modestly. Restructuring, acquisition, integration and other costs also increased, and Depreciation and amortization moved higher. Operating Income advanced, though at a slower rate than net income, because non-operating items helped.
Those items are worth a closer look. Net interest expense fell, and the other, net line swung to a gain from a loss in the prior-year quarter, which had included a loss on the extinguishment of debt. Income tax expense rose. Together, these changes meant pre-tax income and Net Income both grew faster than operating income did.
Why Per-Share Earnings Outran Net Income
GAAP diluted earnings per share rose at a noticeably faster rate than net income, and the main explanation lies in the share count. Diluted weighted average shares fell considerably from the prior-year quarter, following a substantial program of repurchases. The Cash Flow Statement shows the company spent heavily on its own stock during the year to date, although somewhat less than in the same stretch of last year.
The timing of those purchases is instructive. The Equity statement in the quarterly report shows that most of the year's repurchases took place in the second quarter, while activity in the third quarter was negligible. Shares outstanding were essentially unchanged between the end of September and early November, as the filing's cover data shows. The benefit to the per-share comparison therefore reflects earlier Buybacks rather than fresh activity during the quarter.
Adjusted measures tell a more restrained story. Adjusted EBITDA advanced modestly, adjusted net income barely increased and adjusted diluted earnings per share grew moderately, again aided by the lower share count. Adjustments to adjusted EBITDA included stock-based compensation and restructuring, acquisition, integration and other costs. The company states that it has not reconciled adjusted guidance measures to GAAP because it considers doing so impracticable.
The Year So Far Looks Flatter Than the Quarter
Viewed across the year to date, the picture is steadier but less brisk. Net revenue was modestly higher than in the same stretch of last year, and operating income was almost unchanged. Net income rose moderately, helped by lower interest expense and a positive other, net line. Adjusted EBITDA was only slightly higher, while adjusted net income edged lower. Adjusted diluted earnings per share still increased because of the reduced share count.
The third quarter, then, represents some acceleration in revenue compared with the year-to-date pace. Readers may note, however, that the comparison is limited to figures in the release and the filing, and that there is no management commentary to indicate whether the pace reflects therapy mix, volumes or other factors. That absence is a direct consequence of the merger process, and it leaves more of the interpretive work to the financial statements.
Strong Cash Generation Ahead of a Debt-Heavier Future
Cash generation was a clear positive. Operating Cash Flow for the quarter was substantial, and the year-to-date figure was well above that of the prior-year period. Capital spending on property and equipment was little changed. Last year's cash flow included a Business Acquisition that had no counterpart this year. Even after the repurchases, cash and cash equivalents ended higher than at the end of last year.
Inventories fell from the year-end level, while Accounts Payable and Accounts Receivable each rose. Goodwill was unchanged, and long-term Debt edged down. The quarterly report states that an amendment in March substantially increased commitments under the company's revolving Credit facility, leaving a large amount of net availability. Outstanding debt included a first-lien term Loan maturing in the next decade and senior notes maturing at the end of this decade.
These details describe the company's capital position while it remains public. Once the merger closes, the Balance Sheet and capital allocation decisions will sit within a privately held structure. Option Care Health has said it will delist from Nasdaq and become privately held at that point.
Inside the Agreement That Reshaped the Report
According to the joint announcement filed with the SEC, stockholders are to receive a fixed cash price per share under a deal valued in the billions on an enterprise basis. The price represents a substantial premium to the closing price on the day before the announcement. Clayton, Dubilier & Rice would hold a majority interest slightly over half, with McKesson investing for the remainder. A framework allows McKesson to later acquire the Private Equity firm's interest, subject to conditions and regulatory approvals.
The merger agreement names Onyx Bidco LLC as parent and Onyx Merger Sub, Inc. as the merger vehicle, with the company surviving as a wholly owned subsidiary. The board unanimously approved the transaction, and Chairman Harry Kraemer said the board had "unanimously concluded this transaction maximizes value" for stockholders. The closing is expected during the first half of next year, subject to stockholder approval, required regulatory approvals and other customary conditions.
Option Care Health is to remain a separate company led by its own management team and to continue operating as usual, according to the announcement. Chief Executive Officer John C. Rademacher called the agreement "a great outcome for Option Care Health," and a chief executive email to employees filed with the SEC said the deal "does not change" strategy. McKesson would use the equity method to account for its stake and record its share of net income or loss in other income.
How the Market Priced the Deal
According to market data, the shares jumped after the announcement to a level just under the offer price. Market data, in its own report that day, also described a large jump in the shares and a far smaller move in McKesson, and it characterized the purchase as small relative to McKesson's overall business. Because the consideration is fixed, the operating results reported are likely to matter to stockholders chiefly through whatever bearing they have on the deal's completion, rather than through their usual role in valuation.
The release itself makes no statement on the deal's progress beyond confirming the agreement and the resulting changes to guidance and communications. Nor does the release offer a timetable beyond what had already been disclosed. The stockholder vote and regulatory reviews named in the earlier announcement remain the main steps ahead. Advisers named in that announcement include Centerview Partners and Kirkland & Ellis for the company, Debevoise & Plimpton for the private equity firm and Davis Polk & Wardwell and Reed Smith for McKesson, while a group of major banks is arranging financing for the buyers. Market data also placed the transaction alongside the private equity buyout of home health provider Enhabit, a sign of continuing investor interest in care delivered outside the hospital.
Why McKesson and Private Equity Wanted Infusion
The strategic logic of the transaction points beyond this single quarter. McKesson said the Investment aligned with its long-term strategy, citing growth in specialty care, including specialty, rare and orphan therapies and alternate infusion services, along with expanded patient access through community-based, home and ambulatory infusion care. Chair and Chief Executive Officer Brian Tyler called it "an important opportunity." Clayton, Dubilier & Rice partner Sarah Kim said the company "has shown what is possible when high-quality infusion therapy is delivered." The announcement describes McKesson as a diversified healthcare services leader and Clayton, Dubilier & Rice as a private investment firm with offices in New York and London, and the merger communications say the firm has invested a substantial amount of equity capital in healthcare over the past several years.
According to market data, McKesson already operates an infusion network in Canada and the deal would expand its US home infusion footprint. Market commentary described the patient base as large and the network as spread across many locations. It also reported rapid revenue growth in McKesson's oncology and multispecialty segment, which includes infusion services. The wire quoted J.P. Morgan analyst Lisa Gill as saying McKesson's "focus on specialty and the community setting makes this deal appealing," and it said Leerink Partners analyst Michael Cherny viewed the deal as aligning McKesson with the site-of-care shift away from hospital and provider settings.
The Site-of-Care Shift Behind the Sector
That shift has been a recurring theme in infusion services. Market commentary noted growing Demand for home-based care as the US population ages and more patients seek treatment outside higher-cost settings such as hospitals. A market overview from Mertz Taggart, whose materials cover home-based care and infusion, offers additional context, though it dates from a previous year, which limits how far it describes current conditions. It describes hospitals as the original and still primary setting for infusion, with their share expected to decline as lower-cost settings grow.
The overview places home infusion at the low end of the price range among care settings and says patients favor it for convenience and cost savings and are most likely to complete treatment there, while noting that not every therapy is suited to the home. It also says payers are pressing to lower costs, moving intravenous therapy away from higher-cost sites. Home remained a small share of overall infusion spending in that assessment, with hospitals holding the majority, suggesting a long runway but also the competitive presence of physician offices and ambulatory infusion centers.
The overview also reports that commercial payers reimburse the majority of cases, a pattern broadly in keeping with Option Care Health's own disclosure that commercial payers contributed the largest share of its revenue increase. Practices such as white-bagging, in which a payer requires drugs to be obtained from a third-party pharmacy, were identified in the overview as a pressure on provider economics, with some states passing protective laws.
What Remains to Be Watched
With guidance withdrawn and no call scheduled, there will be fewer public signals from the company between now and closing. The main items to monitor are likely to be the stockholder vote, the regulatory reviews and any further filings connected with the agreement. A risk that any pending deal carries is that the expected completion may not happen on the anticipated schedule, and the company's forward-looking disclosures address the merger accordingly.
The third-quarter report leaves a straightforward impression of a company that continued to expand revenue, generate cash and manage its costs while the transaction moved through its early stages. Its most significant news is that there was so little to announce beyond the figures themselves. As long as the merger remains pending, the company's published financial statements, rather than management's forecasts, are the main public record of how the business is performing in what may be among its final quarters as a Nasdaq-listed company.
_11_16_2026_14_38_45_453029.jpg)





Please wait processing your request...